Breast Cancer Radiogenomics: Current Status and Future Directions

Publication date: January 2020Source: Academic Radiology, Volume 27, Issue 1Author(s): Lars J. Grimm, Maciej A. MazurowskiRadiogenomics is an area of research that aims to identify associations between imaging phenotypes (“radio-”) and tumor genome (“-genomics”). Breast cancer radiogenomics research in particular has been an especially prolific area of investigation in recent years as evidenced by the wide number and variety of publications and conferences presentations. To date, research has primarily been focused on dynamic contrast enhanced pre-operative breast MRI and breast cancer molecular subtypes, but investigations have extended to all breast imaging modalities as well as multiple additional genetic markers including those that are commercially available. Furthermore, both human and computer-extracted features as well as deep learning techniques have been explored. This review will summarize the specific imaging modalities used in radiogenomics analysis, describe the methods of extracting imaging features, and present the types of genomics, molecular, and related information used for analysis. Finally, the limitations and future directions of breast cancer radiogenomics research will be discussed.
Source: Academic Radiology - Category: Radiology Source Type: research

Related Links:

DNA changes in a common type of breast cancer cell may be linked to hormone therapy resistance, according to a study published inNature Communications.Science Daily
Source: Society for Endocrinology - Category: Endocrinology Source Type: news
CONCLUSIONS BORG promotes the development of chemoresistance of CRC cells to carboplatin. PMID: 31937750 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
We describe the adaptation of a model-based design for identifying the maximum tolerated dose combination that efficiently moves from the initial phase in an advanced disease population to the second phase in the target population. Operating characteristics demonstrate the ability of the method to accurately predict true maximum tolerated dose combinations in a high percentage of trials with reasonable sample sizes, while treating participants at and around desirable combinations. The proposed design is a practical, early-phase, adaptive method for use with drug combination dose finding in the presence of shifting patient ...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Contemp Clin Trials Commun Source Type: research
Almost half of higher stage of disease at diagnosis in racial/ethnic minorities explained by insurance status
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Family Medicine, Gynecology, Internal Medicine, Oncology, Radiology, Journal, Source Type: news
Conclusions Sentinel lymph node identification using preoperative scintigraphy and intraoperative use of gamma probe seems to be a feasible and efficient method in terms of differentiating patients that require axillary lymph node dissection during breast cancer surgery, even when they have received neoadjuvant chemotherapy. Further large prospective studies allowing subgroup analyses are warranted.
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Original Articles Source Type: research
This study was designed to investigate the role and therapeutic implications of miR-151-5p in breast cancer. The results of the present study revealed that miR-151-5p is significantly downregulated in breast cancer tissues and cell lines. Overexpression of miR-151-5p in SK-BR-3 and CAMA-1 cells inhibits their proliferation and colony formation. Wound heal and transwell assays showed that miR-151-5p inhibits the migration and invasion of the SK-BR-3 and CAMA-1 breast cancer cells. TargetScan analysis followed by the dual luciferase assay confirmed SOCS5 to be the target of miR-151-5p in breast cancer. The expression of SOCS...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
CONCLUSION: The Erk signaling pathway may be crucially involved in the differentiation induction of breast cancer cells in vitro and in vivo. Collectively, our results suggest that the combination can probably serve as promising candidates for the development of novel therapeutic approaches for different types of breast cancer. PMID: 31934280 [PubMed]
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
THURSDAY, Jan. 16, 2020 -- Insurance status and access to care play an important role in racial disparities in stage of breast cancer at diagnosis, according to a study published online Jan. 9 in JAMA Oncology. Naomi Y. Ko, M.D., from the Boston...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Publication date: Available online 16 January 2020Source: Meta GeneAuthor(s): Ahmed Wadaa Allah, Mohammed Yahya, Khaled Saad Elsaeidy, Souad Alkanj, Khaled Hamam, Mohamed El-Saady, Mahmoud Ahmed EbadaAbstractObjectivesmiRNA-23b has been proposed to have a significant role in the prognosis of several types of tumors, despite the potential impact of its expression is still controversial. Innovative prognostic biomarkers for the prediction of cancer outcomes and the usage as therapeutic targets are warranted. We conducted this systematic review and meta-analysis to evaluate the associations between miRNA-23b expression and ov...
Source: Meta Gene - Category: Genetics & Stem Cells Source Type: research
Asking personal assistants like Alexa about complex health issues isn't a reality...Read more on AuntMinnie.comRelated Reading: Are breast density notification laws really working? Breast density laws don't boost ultrasound rates AI beats density for predicting breast cancer risk Breast ultrasound spots more cancers in dense breasts JACR: Breast density notices need improvement
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
More News: Academia | Breast Cancer | Cancer | Cancer & Oncology | Computers | Conferences | Genetics | Learning | Radiology | Universities & Medical Training